Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZOR: BPI-7711 vs Gefitinib in First-Line EGFR-Mutated NSCLC
NCT03866499Phase 3Active, not recruiting
- Sponsor
- Beta Pharma
- Start
- Apr 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rezivertinib in non-small cell lung cancer (NSCLC), sponsored by Beta Pharma. Started Apr 2021; status: active, not recruiting.
02
Drugs
rezivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03866499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866499.